Home/ Supplements/ Niacin/ Exspore

Exspore

product on market Tablet or Pill Nutri-West Safety: 90/100
90/100

This product looks safe

  • Contains proprietary blend — exact ingredient amounts not disclosed
  • 40% of ingredients have research evidence
A Label Compliance Grade

What the Evidence Says

AI-generated · Qwen 3.6 · methodology

Niacin, zinc, and manganese are essential micronutrients that support metabolic function and immune health, with strong evidence for their general physiological roles. Molybdenum also contributes to enzyme activity, though evidence for its specific efficacy in this formulation is limited. The profile maintains a high safety score of 90/100.

AI-generated summary based on research evidence. Not medical advice.

Alerts

Safety Alerts

Contains proprietary blend — exact ingredient amounts not disclosed

Label

Product Label

Label for Exspore
Open Full PDF View on NIH DSLD →
Details

Label Data

1 Tablet(s)
Serving Size
Other Combinations
Product Type
40%
Evidence Coverage
Ingredients

Supplement Facts — Evidence Check

2.5 mg (13% DV)
Within RDA (0.2× RDA) 196 studies (A:5, B:63)
5 mg (33% DV)
Within RDA (0.5× RDA) 263 studies (A:6, B:134)
1 mg (50% DV)
Within RDA (0.4× RDA) 9 studies — no high-quality reviews
25 mcg (33% DV)
Within RDA (0.6× RDA) 3 studies — no high-quality reviews
Proprietary Blend
374.72 mg

Other Ingredients

Dicalcium Phosphate Stearic Acid Magnesium Stearate
Claims

Label Claims — Verification

Unverified All Other
Info

Product Information

Warnings & Precautions

Keep out of reach of children.

Tamper resistant outer seal – do not use if broken.

Additional Information

For distribution by health care professionals only.

Store in a cool, dry place.

“When you want the best”

Metadata

Product Details

DSLD Entry Date2020-02-26
Product TypeOther Combinations
FormTablet or Pill
DSLD ID214608
Data Updated2026-04-11
Research

Research Evidence

241
Research Sources
55
Avg Quality
113
Meta Analysis
75
Systematic Review
32
Rct
11
Clinical Trial
3
Other
3
Regulatory Source
1
Cochrane Review
1
Narrative Review
1
Openfda Safety
A Niacin for primary and secondary prevention of cardiovascular events
Meta Analysis The Cochrane database of systematic reviews 2017 PubMed DOI
A Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases
Meta Analysis BMJ (Clinical research ed.) 2013 PubMed DOI
A Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients
Meta Analysis BMJ (Clinical research ed.) 2014 PubMed DOI
A A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk
Meta Analysis Nature medicine 2024 PubMed DOI
A Meta-analysis and imputation refines the association of 15q25 with smoking quantity
Meta Analysis Nature genetics 2010 PubMed DOI
A Genome-wide meta-analyses identify multiple loci associated with smoking behavior
Meta Analysis Nature genetics 2010 PubMed DOI
A Antidepressants for smoking cessation
Meta Analysis The Cochrane database of systematic reviews 2014 PubMed DOI
A Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne
Meta Analysis The Cochrane database of systematic reviews 2020 PubMed DOI
B Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis
Meta Analysis JAMA network open 2019 PubMed DOI
B Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis
Meta Analysis JAMA 2016 PubMed DOI
View all evidence for Niacin →
Compare

Similar Products

View all Niacin products →

This product page is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before taking any supplement.